Modality
mAb
MOA
BCMA ADC
Target
FGFR
Pathway
Epigenetic
RAMDS
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Sep 2030
Phase 2Current
NCT06506526
1,945 pts·RA
2023-02→2030-09·Completed
1,945 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-254.5y awayPh2 Data· RA
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2030-09-25 · 4.5y away
RA
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06506526 | Phase 2 | RA | Completed | 1945 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |